News regarding Oslo Cancer Cluster Incubator

Image: Shutterstock

NOME Important to BioIndustry Growth

Nordic Mentor Network for Entrepreneurship (NOME) will be an important piece of the puzzle if Norway is going to fulfill their ambitions set by the coming White Paper on the Healthcare Industry.

If we are to make our bioindustry more competitive and take a leading European role within eHealth, we need to learn from the best in the business. NOME is a program that aims to lift Nordic life sciences to the very top by using mentors.

The Norwegian Parliament’s Health Committee has asked for a report on the Healthcare industry in Norway, a so called White Paper. The objective is to examine the challenges we face because of climate change, new technology, robotics and digitalization.

Innovation needs to meet industrial targets
Additionally, the committee has stressed the importance of a purposeful dedication to health innovation. There should be a focused investment In fields where we have special preconditions to succeed. A better facilitation of clinical studies and use of health data is especially emphasized. Nordic countries are in a unique position with vast registries of well documented health data, a good example being the Cancer Registry of Norway. With better implementing of new technology this type of health data will be increasingly important.

The committee also emphasized the need to shorten the distance between research and patient treatment through effective commercialization. And, in continuation, easier access to risk investment capital to help the industry grow.

–The path from research to actual treatments and medication is long and hard, and rightfully so – everything must be thoroughly tested. But you can imagine! Every second we can peel off the time it takes for new research to reach patients is extremely valuable and saves lives, explains Bjørn Klem, Managing Director, Oslo Cancer Cluster Incubator.

NOME a piece of the puzzle
However, how do we fulfill these ambitions? Klem believes the answer is combining forces within the other Nordic countries.

– We have different strengths. Think about how big Bioindustry and business is in Denmark. There is so much to learn form that!

NOME is a concrete way of collaborating. It is easy to say: “we are going to learn from each other”, but how do we in a concrete fashion set about doing this. NOME is a mentoring program that sets collaboration in motion.

— To put it plainly, NOME is a program for all Nordic Bio start-ups. They can apply and if their application is successful we send experts catered to help with the company’s very specific needs, explains Klem.

NOME is a meeting place between the start-up freshman and the experts that have thread this path before. They match Nordic entrepreneurs with handpicked international professionals to help each start-up with their specific needs.

— Think about it! There is so much a new start-up don’t know, lacking network and experience. How do you make it as a commercialized company in the health industry? NOME can provide both business and research mentoring transferring knowledge from past successes to new ones, says Klem.

A Twofold Benefit to Society
The desire is to propel the Nordic countries into one of the leading life science regions to commercialize high growth life science start-ups.

— With NOME society’s return is twofold. Firstly, we give patients access to new treatment faster by giving start-ups the necessary guidance and know-how. Secondly, we give our Bio Business a chance to grow with all the positives that has to economy and employment, Klem believes.

Oslo Cancer Cluster Incubator coordinates the NOME-program in Norway and collaborates with the incubator Aleap to find the best match of mentors and entrepreneurs. To take part in the program you can click here for more information.

Alle finalistene på scenen sammen med Sivas Espen Susegg og Ulf Hustad. Vinnerne, Bjørn Klem, Bente Prestegård og Ketil Widerberg fra Oslo Cancer Cluster, står i midten i hvite t-skjorter. Foto: Siva

Vi vant Siva-prisen 2017!

Oslo Cancer Cluster Incubator stakk av med Siva-prisen for 2017 på årets Siva-konferanse i Trondheim.

Slik beskriver Siva vinneren:

Oslo Cancer Cluster Incubator er en pådriver til utvikling av diagnostikk og behandling av kreftpasienter ved hjelp av ny revolusjonerende teknologi. De jobber med å omsette kreftforskning til nye medisiner og behandlingsformer. Dette gir nytt håp for kreftpasienter og bidrar til en ny helsenæring i Norge. Inkubatoren får daglig besøk av bedrifter, politikere, forskere, elever, gründere og andre som ønsker å lære eller bidra til helseinnovasjon.


Helseinnovasjon
– Alle snakker nå om at helseinnovasjon er viktig. Vi i Oslo Cancer Cluster Incubator er en viktig aktør i innen helseinnovasjon. Vi ønsker å bidra nasjonalt i dette, med en klar tynge på kreft, sier Bjørn Klem, leder for Oslo Cancer Cluster Incubator.

Han er fra seg av glede over at inkubatoren dro i land seieren på årets store Siva-happening, konferansen om den grenseløse industrien, som fant sted i Trondheim tirsdag 9. mai.


Penger til bedre nettverk
Verdiskapning og samarbeid jobber Oslo Cancer Cluster Incubator mye med, og her vil de også bruke gevinsten, som er på 300 000 kroner.

– Vi omstiller norsk næringsliv og vil fortsette med det innenfor helsenæringen. Vi vil bruke gevinsten på å fortsette med det, og på å bedre nettverket mellom klyngene i Norge og Norden, sier Klem.

Oslo Cancer Cluster Incubator kom til finalen sammen med MacGregor Norway og Protomore Kunnskapspark.

– De tre finalistene er formidable nyskapingsmiljøer som i vår bok alle er vinnere. De har på hver sin måte vært pådrivere for nyskaping og bidratt til den omstillingen og utviklingen som næringslivet i Norge er så avhengig av. Når det er sagt vil jeg på vegne av Siva gratulere Oslo Cancer Cluster Incubator med en velfortjent seier. Vi håper de fortsetter det gode og viktige arbeidet med å utvikle medisiner og bedre behandling for kreftpasienter, sier Ulf Hustad, som er prosjektleder for prisen, til Sivas nettside.


En viktig konferanse for inkubatorene

I år kom rekordmange deltakere på Siva-konferansen. De kom fra ulike inkubatorer og næringsklynger, og talte omkring 300 stykker. På konferansen fikk de presentert et nytt initiativ kalt Norsk katapult. Her skal 50 millioner kroner brukes på å etablere såkalte katapult-fasiliteter, testfasiliteter i overgangen mellom forskning og etablert industri.


Om Siva

Siva står for Selskapet for industrivekst SF. Det ble etablert i 1968 og er en del av det næringsrettede virkemiddelapparatet. Siva er statens virkemiddel for tilretteleggende eierskap og utvikling av bedrifter og nærings- og kunnskapsmiljø i hele landet, med et særlig ansvar for å fremme vekstkraften i distriktene. Hovedmålet er å utløse lønnsom næringsutvikling i bedrifter og regionale nærings- og kunnskapsmiljø.

Nominated as “Norway’s smartest industrial company”

Thermo Fisher Scientific is one of three finalists to win the award and title in Oslo this Tuesday.

The technology which the biotech company is nominated for, is development of faster and cheaper DNA-sequencing. More than 70 companies were candidates for this year’s price, according to the Norwegian online tech magazine Teknisk Ukeblad. 

Thermo Fisher Scientific is one of Norway´s leading biotechs and among the most profitable. The company has played a vital role in Norwegian biotech with the development of «Dynabeads», used all over the world to separate, isolate and manipulate biological materials.

The smart element
On the question “why are you in the finals”, Ole Dahlberg, CEO at Thermo Fisher Scientific in Norway, is quick to answer.

“We have been capable of combining an established, older technology with another technology, creating maybe the most powerful tool for gene sequencing that we have in the world today”, says Dahlberg.

The smart element was using the beads in a completely new way on a microchip in combination with semiconductor technology. This link between biotech and electronics has created the instruments from Thermo Fisher which we now see in research institutes and diagnostic labs all over the world.

Ole Dahlberg, CEO at Thermo Fischer Scientific Norway, believes in their smart element.

Industrialising technology
What Thermo Fisher did, was to reduce the size of traditional magnetic beads to nano size. This resulted in much more efficient production methods. The number of people involved in the production of the beads, as well as the production time, could thereby be reduced.

Today, one person can produce ten times more beads in a day than 10-15 people could before, due to the new production technology, developed in-house.

Thermo Fisher’s Dynabeads are used in basic research, in billions of diagnostic tests, as well as in immunotherapy, all over the world. Innovation and further applications are being developed in close collaboration with research environments, clinics and industrial partners.

The importance of collaboration
“All the products we have developed, and those are quite a few, are developed in collaboration with academia and the clinical part of hospitals and other companies”, says Dahlberg.

His company has had a close collaboration with OUS Radiumhospitalet and SINTEF, and today it is part of Oslo Cancer Cluster and has offices in the Oslo Cancer Cluster Incubator.

“We greatly believe in this kind of collaboration. It creates trust. One of the interesting things with the cluster is that it leans over in education. We need a broader interest for biotechnology and life science among the young, and we also recruit a lot of young people”, says Dahlberg.

A smart approach
Thermo Fischer Scientific gets their smart young coworkers directly from Norwegian universities like NTNU and UiO, as well as from abroad.

“We use a smart approach. It is all about putting the team first and making sure that the people who work here are dedicated and proud of our products”, says Dahlberg.

9 May is the day the winner will be announced at the Norwegian conference Industrikonferansen in Oslo, held by the union Norsk Industri, part of NHO.

 

About Thermo Fisher Scientific
Thermo Fisher Scientific in Norway was established in 1986. The company focuses on the diagnostics market as well as the development of innovative immunotherapeutics, especially within oncology. The client portfolio features many of the world’s largest pharma and diagnostics companies. In 2014 the company had 180 employees and a turn-over of 760 MNOK. The company has production units both in Oslo and Lillestrøm. The Norwegian company is a subsidiary to Thermo Fisher Scientific. Read more at www.thermofisher.com

More about cancer research in Thermo Fisher.

 

 

OncoImmunity AS wins the EU SME Instrument grant

The bioinformatics company OncoImmunity AS was ranked fourth out of 250 applicants for this prestigious grant.

250 companies submitted proposals to the same topic call as OncoImmunity AS. Only six projects were funded.

We applied for the SME instrument grant as it represents an ideal vehicle for funding groundbreaking and innovative projects with a strong commercial focus. The call matched our ambition to position OncoImmunity as the leading supplier of neoantigen identification software in the personalised cancer vaccine market”, says Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity.


Personalised cancer vaccines
Neoantigen identification software facilitates effective patient selection for cancer immunotherapy, by identifying optimal immunogenic mutations (known as neoantigens). OncoImmunity develops proprietary machine-learning software for personalised cancer immunotherapy.

This solution also guides the design of neoantigen-based personalised cancer vaccines and cell therapies, and enables bespoke products to be developed faster.

The SME Instrument gives us the opportunity to further refine and optimise our machine-learning framework to facilitate personalised cancer vaccine design. This opportunity will help us establish the requisite quality assurance systems, certifications, and clinical validation with our partners, to get our software accredited as an in vitro diagnostic device”, says Dr. Richard Stratford.

In vitro diagnostics are tests that can detect diseases, conditions, or infections.

Dr. Richard Stratford is Chief Executive Officer and Co-founder of OncoImmunity, member of Oslo Cancer Cluster and part of the Oslo Cancer Cluster Incubator.


Hard to get
Horizon 2020’s SME Instrument is tailored for small and medium sized enterprises (SMEs). It targets innovative businesses with international ambitions — such as OncoImmunity.

“The SME instrument is an acid test; companies that pass the test are well suited to make their business global. It also represents a vital step on the way to building a world-class health industry in Norway”, says Mona Skaret, Head of Growth Companies and Clusters in Innovation Norway.

The SME Instrument has two application phases. Phase one awards the winning company 50 000 Euros based on an innovative project idea. Phase two is the actual implementation of the main project. In this phase, the applicant may receive between 1 and 2,5 million Euros.

The support from the SME instrument is proof that small, innovative Norwegian companies are able to succeed in the EU”, says Mona Skaret.

You can read more about the Horizon 2020 SME Instrument in Norwegian at the Enterprise Europe Network in Norway.

 

Thinking of applying?
Oslo Cancer Cluster helps its member companies with this kind of applications through the EU Advisor Program and close collaboration with Innovayt and Innovation Norway.

The SME Instrument is looking for high growth and highly innovative SMEs with global ambitions. They are developing innovative technologies that have the potential to disrupt the established value networks and existing markets.

Companies applying for the SME Instrument must meet the requirements set by the programme. Please see the SME Instrument website for more information.

Join NOME – Nordic mentoring programme for life sciences companies

NOME is the first Nordic mentor network connecting prospective life science entrepreneurs with handpicked international mentors.

The goal is simple: to help the very best biotech and medtech startups in the Nordics to become the next growth successes. Oslo Cancer Cluster Incubator coordinates the NOME-programme in Norway and collaborates with Oslo Medtech and the incubator Aleap to find the best match of mentors and entrepreneurs.

 

Watch the NOME information video here

Contact Bjørn Klem, General Manager of Oslo Cancer Cluster Incubator, if you would like to join NOME or if you want more information about the programme in Norway.

Take a look at the NOME website and the information flyer for more information about the programme. 

 

The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway

The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway

Oslo (Norway), 6 January 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer, today announced that they are awarded NOK 500,000 for further development of the existing preclinical research collaboration. The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies and the grant will support these activities. The Innovation Norway grant of NOK 500,000 is awarded for 2017 and the grant is made available through Oslo Cancer Cluster a Norwegian Centre of Expertise.

Please see attached press release for further details.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

 

Innovasjonsrammen 2016

Det overordnede målet med Innovasjonsrammen 2016 er å stimulere til økt innovasjon gjennom flere felles innovasjons- og forskningsprosjekter mellom bedrifter.

Midlene skal brukes til mobilisering av utviklingsprosjekter og til idé- og prosjektutvikling (konseptualisering). Innovasjonsrammen 2016 skal bidra til at samarbeidsprosjektene kommer i posisjon til å få finansiering gjennom Forskningsrådets og Innovasjon Norges ordinære ordninger eller fra private investorer.

Oslo Cancer Cluster har fått tildelt en rammebevilgning på en million kroner, som kan trekkes på etter saksbehandling og innvilgning fra Innovasjon Norge. Klyngen forestår selv prioriteringer av egne prosjekter innenfor rammen ved at daglig leder eller en med mandat fra daglig leder anbefaler søknaden på vegne av klyngen. Prioriteringene skal være gjort i samråd med klyngens styre.

Prosjektene må innfri kravene for støtte til eksperimentell utvikling (FoUI) i statsstøtteregelverket. Et av kravene er at støtten kun kan gis til èn bedrift eller ett kompetansesenter. Søker kan imidlertid få dekket kostnader ved kjøp av tjenester fra partnere i samarbeidsprosjektet.

Innovasjonsrammen stiller krav til at midlene kun benyttes til samarbeidsprosjekter der minimum to virksomheter inngår (merk; minst en av bedriftene må være partner eller medlem i klyngen).

Tilskudd fra Innovasjonsrammen 2016 gis i tråd med regelverket for støtte til eksperimentell utvikling (FoUI-støtte) i statsstøtteregelverket. Støtten skal gis på områdene mobilisering og konseptualisering. Regelverket åpner for 25-45% støtte avhengig av bedriftenes størrelse samt 15% i samarbeidsbonus.

Interesserte bedrifter i Oslo Cancer Cluster bes ta kontakt med bk@occincubator.com for mer informasjon og søknadsskjema. Søknadene vil vurderes av et ekspertpanel, og innleveringsfristen for søknaden er 7.september.

På vegne av Oslo Cancer Cluster

Bjørn Klem

Nadine Lohs hired as Operation Manager

The Oslo Cancer Cluster Incubator has recruited Nadine Lohs to be responsible for the operation of the Incubator from 1st August.

Nadine Lohs is from Austria and has recently completed her Master of International Health and Social Management at the Management Center Innsbruck. She has had an internship at Oslo Cancer Cluster Incubator this Spring.

Contact details:

E-mail: nadine@occincubator.com

Phone: 90 76 23 63

Thermo Fisher Scientific will create Google-like envionment for biotech in the Oslo Cancer Cluster Incubator

Thermo Fisher Scientific will rent over 800m2 in the Oslo Cancer Cluster Incubator. Here, the company will create a creative Google-like environment with a particular focus on diagnostics and the development of new treatments using cancer immunotherapy.

 

 Thermo Fisher Scientific is one of Norway´s leading biotechs and among the most profitable. The company is expanding and during the first quarter of 2016 the entire management team, production team and parts of the R&D milieu will move to the Oslo Cancer Cluster Incubator. Here, 800m2 will be set up like a creative Google-like office space.

– We are really pleased that Thermo Fisher Scientific chooses to move into Oslo Cancer Cluster Incubator. The company, which initially was established as Dynal in 1986, has played a vital role in Norwegian biotech with the development of «Dynabeads» that is used all over the world. Their record of accomplishment of bringing innovative products to the market is impressing. For the environment in the incubator it is crucial to have a global, experienced actor present, says Bjørn Klem, CEO Oslo Cancer Cluster Incubator.

 

Strong in immunotherapy

The overall aim of the Oslo Cancer Cluster Incubator is to contribute to the successful development of oncology biotechs so that they may reach the market with their innovative treatments against cancer. The cancer R&D milieu in Norway in general is strong within cancer immunotherapies, which is also the case with the incubator companies.

– Thermo Fisher´s «Dynabeads» is used in basic research, in billions of diagnostic tests as well as in immunotherapy all over the world. Innovation and further applications is developed in close collaboration with research environments, clinics and industrial partners. Oslo Cancer Cluster has become one of the leading innovation clusters and we would like to take an active role in further developing the cluster. We think that co-localisation with the milieu in the incubator will be a catalyst for our growth and innovation in the future, says Ole Dahlberg, CEO Thermo Fisher Scientific in Norway.

 

Facts: 

Thermo Fisher Scientific:
Thermo Fisher Scientific in Norway (former Dynal Biotech) was established in 1986. The company focuses on the diagnostics market as well as the development of innovative immunotherapeutics, especially within oncology. The client portfolio features many of the world’s largest pharma and diagnostics companies. In 2014 the company had 180 employees and a turn-over of 760 MNOK. The company have production units both in Oslo and Lillestrøm. The Norwegian company is a subsidiary to Thermo Fisher Scientific which is listed on NYSE. www.thermofisher.com


In Norwegian:

Thermo Fisher Scientific inn i Oslo Cancer Cluster Inkubator: Styrker miljøet rundt immunterapi mot kreft

Thermo Fisher Scientific skal leie over 800m2 i Oslo Cancer Cluster Incubator. Selskapet skal skape et kreativt ‘Google-aktig landskap’ innen bioteknologi med særlig fokus på diagnostikk og utvikling av nye former for behandling ved bruk av immunterapi.

Thermo Fisher Scientific er et av Norges største biotekselskap og blant de mest lønnsomme. Selskapet utvider og flytter nå hele ledergruppen og produktorganisjasjonen, samt deler av sitt forsknings- og utviklingsmiljø over til Oslo Cancer Cluster Inkubator. I 5.etasje i inkubatoren skal over 800m2 omgjøres til et kreativt landskap for ansatte i selskapet med fokus på forskning og utvikling innen diagnostikk og immunterapi mot kreft.

– Vi er utrolig glade for at Thermo Fisher Scientific velger å flytte inn i Oslo Cancer Cluster Inkubator. Selskapet, som startet som Dynal i 1986 er en viktig del av norsk bioteknologihistorie med sin utvikling av «Dynabeads»  basert på Ugelstadkulene. De har vist gjentatte ganger at de kan kommersialisere god forskning. Det vil bety mye for resten av miljøet i inkubatoren å ha med en så erfaren aktør med global tilstedeværelse, sier Bjørn Klem som er daglig leder i Oslo Cancer Cluster Incubator.

 

Viktig for et Norge i omstilling

Oslo Cancer Cluster Inkubator skal bidra til at flere selskaper lykkes med å utvikle sin behandling av ulike kreftformer. Immunterapi mot kreft er en helt ny måte å behandle kreft på der kroppens eget immunforsvar aktiveres for å bekjempe kreftcellene. Miljøet i inkubatoren er særlig sterke innen dette fagfeltet, som blir ytterligere styrket ved at immunmonitoreringsenheten ved seksjon for celleterapi ved Oslo universitetssykehus, Radiumhospitalet flytter inn med syv ansatte i tillegg til Thermo Fisher Scientific.

 

– Thermofisher sine «Dynabeads» brukes i dag innen grunnforskning, til milliarder av diagnostiske tester og nå innen immunterapi. Innovasjon og applikasjonsutvikling skjer i nært samarbeid med forskningsmiljøer, klinikker, og industrielle partnere. Oslo Cancer Cluster har demonstrert høye ambisjoner og gjennomføringsevne på å bli en av de ledende innovasjonsklyngene og vi ønsker å være en del av det. Samlokalisering og felles aktiviteter med klinikken og andre selskaper tror vi er en katalysator for vår vekst og innovasjonsgrad fremover, sier Ole Dahlberg, administrerende direktør i Thermo Fisher Scientific i Norge.

 

– Statsminister Erna Solberg sa da hun åpnet Oslo Cancer Cluster Innovasjonspark og inkubator i august i år at helseindustri er en industri med dobbel gevinst: Fremskrittene som gjøres bidrar til velferd og helse samtidig som de skaper verdier og arbeidsplasser. Vi er overbevist om at det norske kreftforskning- og utviklingsmiljøet kan bety mye for et Norge i omstilling, samtidig som vi utvikler morgendagens kreftbehandling, sier Ketil Widerberg, daglig leder i Oslo Cancer Cluster.

 

Kontaktpersoner:

Oslo Cancer Cluster Inkubator: Bjørn Klem, daglig leder: e-post: bk@occincubator.com mobil: 924 161 56

Oslo Cancer Cluster: Ketil Widerberg, daglig leder: e-post: kw@oslocancercluster.no, mobil: 915 77 990

Thermo Fisher Scientific: Ole Dahlberg, adm.dir, e-post: ole.dahlberg@thermofisher.com, mobil 91108260 eller Geir Hetland, finansdirektør, e-post: geir.hetland@thermofisher.com, mobil: 98218280

 

Thermo Fisher Scientific:
Thermo Fisher Scientific i Norge (tidl Dynal Biotech) ble etablert i 1986. Selskapet har fokus på det diagnostiske markedet samt utvikling av nye former for immunterapi spesiellt innenfor kreftområdet. Kundeportoføljen består av mange av verdens største pharma og diagnostiske selskaper i verden. I 2014 hadde selskapet 180 ansatte og omsatte for 760 millioner. Selskapet har produksjonslokaler både i Oslo og Lillestrøm. Det norske selskapet er et datterselskap til Thermo Fisher Scientific som er et børsnotert selskap på NYSE. www.thermofisher.com

 

 

 

 

 

 

 

 

 

 

HealthCap opens office in Oslo Cancer Cluster Incubator

HealthCap, a leading life science venture capital firm, has opened office in the newly established incubator in the Oslo Cancer Cluster Innovation Park. HealthCap also becomes a member of the Oslo Cancer Cluster.

 

HealthCap recognizes the emerging life sciences industry in Norway. “The strong environment created in the dedicated oncology cluster, bringing together all parts of the oncology value chain at the world renowned Radiumhospitalet, holds promise to play an important role in the development of the next generations of oncology treatments. We look forward to take part in and contribute to this important endeavor”, says Björn Odlander, managing partner of HealthCap.

HealthCap has retained Ludvik Sandnes to supervise the Norwegian operations. Ludvik Sandnes is a special advisor to HealthCap and has more than 40 years of experience from international corporate finance and asset management. He is currently the chairman of the listed Norwegian oncology company Nordic Nanovector AS.

 

HealthCap will host a seminar at the Oslo Cancer Cluster Innovation Park on December 9th at 12.30.
Please sign up here, the program will be published shortly.

The CEO of Oslo Cancer Cluster and Chairman of the Board of Oslo Cancer Cluster Incubator, Ketil Widerberg says “We are extremely happy to have HealthCap on board both in the Oslo Cancer Cluster and in the Incubator. HealthCap´s track record of investing in life science is impressing, and their competence and network will be valuable for further building a viable oncology industry based on excellent cancer research at Norwegian academic institutions.”

HealthCap invests in companies developing targeted therapies for rare diseases, cancer and genetic diseases, among others. HealthCap was the lead investor in the Norwegian oncology company Algeta, which was acquired by Bayer for USD 2.9 bn, and is the largest shareholder in the Norwegian oncology companies Nordic Nanovector AS and Targovax AS.

Purely focused on oncology, the Oslo Cancer Cluster Innovation Park and Incubator, will ensure that bright ideas in the lab benefit cancer patients faster than today.

 

For more information, please contact:

Björn Odlander, managing partner HealthCap,  email: bjorn.odlander@healthcap.eu, phone: +46 8 442 58 50

Johan Christenson, partner HealthCap, email: johan.christenson@healthcap.eu, phone: +46 8 442 58 50

Ketil Widerberg, CEO Oslo Cancer Cluster and Chairman of the Board Oslo Cancer Cluster Incubator, email: kw@oslocancercluster.no, phone: +47 915 77 990

 

Facts:

HealthCap:
HealthCap is a leading European venture capital firm investing exclusively and globally in life sciences. A cornerstone of the strategy is to invest in companies developing therapeutic interventions that have the potential to significantly improve patient outcomes. HealthCap backs companies developing targeted therapies for rare diseases, orphan drugs, cancer and genetic diseases, among others. The HealthCap team of ten partners, five of whom are MD PhDs, has established its reputation as one of Europe’s preeminent life science specialists amongst VCs and entrepreneurs. See more at: www.healthcap.eu

 

Oslo Cancer Cluster
Oslo Cancer Cluster is a strong biotech cluster well positioned in the global oncology industry. The cluster is particularly strong in immuno-oncology and works to release the potential that lies within Norwegian oncology registries and bio banks. 70 members make up the cluster and represent the entire oncology value chain. www.oslocancercluster.no

 

Oslo Cancer Cluster Incubator
Oslo Cancer Cluster Incubator offers lab and office space to researchers and biotechs developing cancer treatments, as well as companies offering competence, services and an international network crucial to succeed in this globally competitive area. The incubator´s over all aim is to develop more companies based on excellent cancer research as well as to contribute to their success. Today, more than X companies are part of the incubator. www.occincubator.com

 

Oslo Cancer Cluster Innovation Park AS

Total space: 36 000 m²

Vision: The vision of the Oslo Cancer Cluster Innovation Park is to create Europe’s leading environment for education, research and industry within oncology, while also shortening the time it takes to develop new cancer medication and diagnostics.

Tenants: Oslo University Hospital, The Institute for Cancer Genetics and Informatics, Norwegian Cancer Registry, Oslo Cancer Cluster SA, Oslo Cancer Cluster Incubator AS, The Norwegian Radium Hospital Research Foundation, The Oslo Hospital Pharmacy, Ullern High School and leading Norwegian biotech companies such as Ultimovacs and PCI Biotech.

Owners: OBOS, Industrifinans, Radium Hospital Foundation, Utstillingsplassen Eiendom, Oslo Cancer Cluster and Oslo Cancer Cluster Incubator.

Opened officially August 24 2015 by the Prime Minister of Norway, Erna Solberg.

www.occinnovationpark.com

 

Oslo Cancer Cluster Incubator: Hottest bioincubator in the Nordics

According to The European Biotech News Website, Oslo Cancer Cluster Incubator is ranked as the hottest bioincubator in the Nordics as well as the 6th hottest bioincubator in Europe. The Top 10 ranking is subject to several criteria. You may read the whole list here.

Oslo Cancer Cluster Incubator just opened its premises in the Oslo Cancer Cluster Innovation Park August this year and is home to around 20 companies,  instituitons and consultants.

The incubator´s ultimate goal is to contribute to the succesful commercialisation of cancer research performed in Norway. This will provide patients with new cancer treatments and at the same time build a much needed knowledge based health industry in Norway.

 

Oslo Innovation Week opening will be streamed

Oslo Innovation Week will be opened today, Monday October 12 at 12 o´clock. The opening is streamed and may be watched here: https://feat.fm/oiw/. Both the Minister of Finance Siv Jensen, and the Minister of Trade and Industry, Monica Mæland will be present at the opening to launch a new plan for Norwegian entrepreneurship. 

 

Oslo Innovation Week will go on the whole week – see all about it on the official website here: www.oiw.no. Follow and join discussions on Social Medias using #oiw.
At our Events page, you may see which seminars Oslo Cancer Cluster is engaged in.

 


In Norwegian:

Finansminister Siv Jensen og næringsminister Monica Mæland vil delta på åpningen av Oslo Innovation Week og lansere gode nyheter for alle Norges entreprenører og gründere.

For alle de som ikke har mulighet til å delta på selve åpningen i Operaen i Oslo så vil den bli streamet på:  https://feat.fm/oiw/. Sendingen starter mandag kl. 12. I statsbudsjettet foreslår regjeringen tiltak for tilsammen 400 millioner “for å få frem gode gründere”.  Hva vil statsrådene presentere? Delta i debatten og bli med live!

 

 K Teams Boston: 9-20 November, 2015.

Opportunity for Oslo Cancer Cluster SMB´s: K Teams is a two week, intensive entrepreneurial training program in Boston and Cambridge. It is a great way to get a company started in the US. Please go to the following link for more information: http://kendall-teams.com/

The team behind the program is a seasoned, experienced group who have helped others companies make a successful entry into the US.  Boston is one of the most vibrant medical technology and bio/pharma regions in the US.

For more info:

Ron Sutherland, Launch in US Alliance: +1 617-407-0722 // rsutherland@launchinus.com

Oslo Cancer Cluster Incubator filling up

12 companies will have offices and lab in Oslo Cancer Cluster Incubator from August on. Bjørn Klem, General Manager of the Incubator, anticipates full house by January 2016.

– If each and every company we have given a quote so far, accepts, we actually are over booked. As of now, we have a good mix of companies. We look forward to have even more start-ups as a result of the activity in Oslo Cancer Cluster Innovation Park and the increased focus on commersialization of cancer research the building represents, says Klem.

The companies will start moving into the Incubator the first week of August, and from then on it is business 24/7. The Oslo Cancer Cluster Managament Team will support the incubator companies with competence within business development, communication, partnering, investor contacts and so on thorugh Oslo Cancer Cluster´s extensive network.

 

Overview Oslo Cancer Cluster Incubator companies as of mid-June:
See profiles of the companies on the Oslo Cancer Cluster Incubator website

  • DNB
  • Curida
  • Intersint
  • Ultimovacs
  • Inven2
  • Lifandis
  • Medivir
  • Pharmalink
  • Normetrix
  • Lytix Biopharma
  • Radium Hospital Research Foundation
  • Oslo Cancer Cluster Management Team

 

 

Oslo Cancer Cluster Incubator receives SIVA-funding

The governmental agency SIVA will support the Oslo Cancer Cluster Incubator with MNOK 15 over the next 10 years in order to develop cancer treatment from companies that spins out from strong cancer research.

– Oslo Cancer Cluster is leading within a research field that is of great importance for Norway and the World. An Incubator will contribute to more commersialisation, more start-ups and a faster way to the market, says Roy Strømsnes, Head of Communcation in Siva.

Bjørn Klem, General Manager of the Incubator, is very pleased with the support from Siva.

– The  support from SIVA is very important for us. The road to the market for cancer biotechs is demanding, and it is crucial to support the start-ups in the critical first years in order to create more succeful companies.

The Oslo Cancer Cluster Incubator will be situated in the Oslo Cancer Cluster Innovation Park, that will open in August 2015.

 


Read the press release here – Norwegian only:

Krafttak for norsk kreftindustri

 Siva støtter Oslo Cancer Cluster Inkubator med totalt 15 millioner til å utvikle kreftbehandling fra bedrifter som bygger på sterk norsk kreftforskning.

Hvert år får omtrent 30 000 nordmenn kreft. Ringvirkningene er store i kjølvannet av en slik beskjed, både for den det gjelder, familie, venner og jobb. Heldigvis blir mange friske eller lever godt med kreften.

Mest solgte i verden
Det er likevel mange kreftformer vi ikke klarer å behandle, og tradisjonell kreftbehandling som stråling og kjemoterapi har alvorlige bivirkninger. Dette er grunnen til at Oslo Cancer Cluster Inkubator åpner dørene neste år, med mål om å utvikle morgendagens kreftbehandling fra norsk kreftforskning i verdensklasse. Dette vil utgjøre en forskjell for kreftpasienter over hele verden, ikke bare i Norge.

Kreftmedisinen Algeta utviklet til behandling av menn mer prostatakreft med spredning som kom på markedet i 2013, var i 2014 den den femte mest solgte nye kreftmedisinen i verden. Dette viser hvor stort behov det er for nye, innovative behandlinger og at norske bedrifter er helt i front.

– Oslo Cancer Cluster er ledende innen et forskningsfelt som har enorm samfunnsverdi for Norge og verden. En inkubator vil bidra til mer kommersialisering, flere nyetableringer og raskere vei fra laboratorium til marked, sier Roy Strømsnes som er kommunikasjonsdirektør i Siva.

Skal få støtte til suksess
Oslo Cancer Cluster Inkubator skal hjelpe flere kreftselskaper å lykkes med å utvikle sin behandling av ulike kreftformer.

– Hos oss skal forskerne og gründerne få leie lab, kontorplass og samtidig ha tilgang til et nettverk av kompetansepersoner som de kan trekke på når de trenger det. Veien til markedet er krevende, og vi skal hjelpe bedriftene i den kritiske oppstartsfasen for å skape flere suksesbedrifter, sier Bjørn Klem som starter som leder av Oslo Cancer Cluster Incubator i januar 2015.

Klem viser til at da det norske kreftselskapet Algeta ble solgt for 18 milliarder norske kroner til Bayer, så styrket den norske kronen seg.

Kommersialiseringsselskapet Inven2 mener Oslo Cancer Cluster Inkubator vil være med å bygge norsk helsindustri.

– Oslo Cancer Cluster Inkubator er en svært viktig byggestein på veien mot en slagkraftig helsenæring i Norge. Der vil oppstartselskaper møte stor industri og være tett på banebrytende kreftforskning, og inkubatoren vil gi dem større sjanser for å lykkes med å bringe nyttige produkter til markedet, sier Ole Kristian Hjelstuen, daglig leder i Inven2.

Betyr mye for pasientene
Oslo Cancer Cluster er overbevist om at inkubatoren som nå skal utvikles vil bety mye for kreftpasienter over hele verden.

– Vi er utrolig glad for denne støtten fra Siva, dette betyr mye for bransjen og vil bety mye for pasientene. Siva er også en av eierne av Oslo Cancer Cluster Innovasjonspark, som gjør at vi får samlet hele verdikjeden innen kreftforskning- og utvikling på ett sted i Oslo, sier Ketil Widerberg, leder av Oslo Cancer Cluster som er en nettverksforening som samler hele kreftmiljøet i Norge og knytter det opp mot lignende organisasjoner internasjonalt.

Oslo Cancer Cluster har siden 2010 hatt en liten inkubator i sine kontorlokaler på Lysaker og har bare god erfaringer med det.

– Vi ser at det å sitte sammen gir gunstige synergier og det er flere av selskapene som har kommet lengre enn antatt med utviklingen av sine kreftbehandlinger på grunn av dette, sier Widerberg.

Kontaktpersoner:

Oslo Cancer Cluster Inkubator:
Bjørn Klem // daglig leder // mobil: 92 41 61 56

Oslo Cancer Cluster:
Ketil Widerberg // daglig leder // 915 77 990

Siva
Roy Strømsnes // kommunikasjonsdirektør // 909 3 3 114
Om oss:

Oslo Cancer Cluster Inkubator

Oslo Cancer Cluster Inkubator tilbyr kontor og laboratorier til forskere og start-ups som utvikler kreftbehandling. I tillegg får leietagerne tilgang på et bredt nettverk av kompetente støttespillere. Målet til inkubatoren er å utvikle flere bedrifter fra norsk kreftforskning, samt bidra til at bedriftene lykkes. Det er per i dag noe ledige lokaler i Inkubatoren som åpner offisielt 24. august 2015.
www.occincubator.com

Oslo Cancer Cluster

Oslo Cancer Cluster er en not-for-profit medlemsorganisasjon som samler hele kreftmiljøet i Norge. Klyngen er i tillegg den eneste innen helse som har status som Norwegian Center for Expertise. Vår visjon er å akselerere utviklingen av morgendagens kreftbehandling til det beste for kreftpasientene. www.oslocancercluster.no

Siva

Siva gir næringslivet rom til å vokse gjennom å investere i eiendom, innovasjonsselskap og utvikling av oppstartsmiljø. Selskapets hovedmål er å utløse lønnsom næringsutvikling i bedrifter og regionale nærings- og kunnskapsmiljø. Siva er et statsforetak eid av Nærings- og fiskeridepartementet. www.siva.no

Inven2

Inven2 er innovasjonsselskapet til Oslo universitetssykehus og Universitetet i Oslo, og kommersialiserer idéer fra forskningen. I 2013 opprettet Inven2 syv selskaper og inngikk 31 lisensavtaler. Selskapsporteføljen til Inven2 er på 32 selskaper og er nå verdt 1,6 milliarder kroner, inkludert en rekke selskaper som utvikler legemidler mot kreft. www.inven2.no

 

Gunnar Gårdemyr appointed CEO in Targovax

The board of Targovax is pleased to announce Mr. Gunnar Gårdemyr as the new CEO from January 12th, 2015.

Mr Gårdemyr has more than 30 years of international experience from the pharmaceutical and biotech industry. His experience includes management, business development, mergers & acquisitions, global marketing and commercial strategy. He holds the position as Corporate Advisor for Acino Pharma in Basel, Switzerland today. Prior to this position, he was Senior Vice President, Corporate Development/M&A, Global Business Development, Nycomed and Senior Vice President, Global Marketing, Takeda in Zurich, Switzerland, where he was in charge of the commercial assessment of external business development licensing opportunities.

Mr Gårdemyr started his career in Astra, followed by Ferring, Tigran Technologies and Retinalyze.

He has a Bachelor of Science in Business Administration and Economics from the University of Lund, Sweden.

Jónas Einarsson, Chairman of Targovax, says, “We are delighted to welcome Gunnar Gårdemyr to Targovax. Our ability to attract an experienced industry executive with Gunnar’s track record and knowledge reflects Targovax` potential. His leadership will accelerate the company’s further development”.

“We are very grateful to Hanne Mette D. Kristensen for her contribution by leading Targovax from establishment to a phase II company”, says Jónas Einarsson.

 

Facts:

Targovax
Targovax was established in October in 2010 to develop immunotherapy in the form of therapeutic cancer vaccines based on pioneering research at the Norwegian Radium Hospital and Norsk Hydro. Mutation of RAS is an early mutation in the transformation of a normal cell into a cancer cell. Lead candidate TG01 educates the body’s immune system to recognize and kill cancer cells with RAS mutations. TG01 has Orphan Drug status for pancreatic cancer in the EU and US and is currently in Phase II trials in operated pancreatic cancer, patients start treatment up to 12 weeks after surgery. The company is located in Lysaker, close to Oslo, Norway.
www.targovax.com

 

 

 

 

 

 

 

Bjørn Klem new General Manager for Oslo Cancer Cluster Incubator

Oslo Cancer Cluster Incubator is delighted to inform that Bjørn Klem has been hired as General Manager. He will start January 1st 2015.

Bjørn Klem is coming from Photocure where he is Project Director. He has been with the company for 17 years. In Photocure, Klem has been in charge of exploratory projects including clinical development of both Metvix® and Hexvix®, Lumacan and Allumera. Both Metvix® and Hexvix® have successfully been introduced to markets world-wide.

At the moment he is in charge of another project, Cevira, for treatment oncogenic HPV infections. This project is about to enter phase III in clinical development. Klem has also been working with market access and out-licensing of Cevira.

An asset for the Incubator
“We are very happy to have Bjørn on board as the first General Manager of the Oslo Cancer Cluster Incubator. He is in deed the right man for this job, based on his long experience with taking products all the way to the market. I am certain that the start-ups in the Incubator will get just the coaching and support they need from Bjørn and the team he will set up,” says Ketil Widerberg, General Manager of Oslo Cancer Cluster.

Oslo Cancer Cluster Incubator is currently situated at Lysaker, where the Incubator is sharing office space with the Management Team of Oslo Cancer Cluster, Pharmalink Oncology, Targovax and the Radium Hospital Research Foundation –  plus Nansen Neuroscience Network.

Symbiotic environment
In July 2015 all these actors will move to the brand new Oslo Cancer Cluster Innovation Park at Montebello, right next to the Norwegian Radium Hospital and The Institute of Cancer Research at Oslo University Hospital. The Incubator will provide a symbiotic environment for scientists and biotech companies working in oncology. The aim is to promote development of novel diagnostics and treatments, and make them accessible to patients world wide.

“The Radium Hospital Innovation Campus is designed specifically to facilitate interactions between all players in this field (scientists, entrepreneurs, investors, biotech companies and providers) in the belief that “We are better than I”. We are now signing contracts with institutions and companies that want to be part of this adventure and would like to hear from you too,” says Bjørn Klem.

He will start full time as General Manager for the Oslo Cancer Cluster Incubator January 1st 2015. Mr. Klem is currently the Chairman of the Board of Oslo Cancer Cluster and Oslo Cancer Cluster Incubator, positions he will resign from due to his new obligation.

 

 

Position open as General Manager for Oslo Cancer Cluster Incubator

Oslo Cancer Cluster Incubator AS is looking for a General Manager. Oslo Cancer Cluster Incubator is a private company, 100% owned by Oslo Cancer Cluster SA. The Incubator will be the provider of infrastructure and  services to researchers and biotech startups to accelerate the development of new cancer treatments.

Oslo Cancer Cluster Incubator is seeking a General Manager whom will be commercial responsible, as well as responsible for the services provided by the Incubator to foster accelerated development and innovation amongst incubator members and rentals. Position to be filled as soon as possible. The Incubator will occupy the entire 4th floor of Building C in Oslo Cancer Cluster Innovation Park, opening medio 2015.

Requirements:
Academic back-ground and experience from industrial development and business development in Life Science, ideally in oncology. This includes understanding of basic research, IPR, funding, clinical and commercialization of research.

Questions regarding the position may be directed to Ketil Widerberg, General Manager Oslo Cancer Cluster:
Mobile:  +47 91 577 990
E-mail: kw@oslocancercluster.no

Application deadline:
September 7th at 20:00 on e-mail to kw@oslocancercluster.no

For more information: occincubator.com

Protecting oncology innovations – download presentations

Researchers, clinicians and start-ups filled up the seminar room when Oslo Cancer Cluster Incubator together with the Norwegian Industrial Property Office (Patentstyret) and Inven2 invited to a breakfast meeting on June 18th. The breakfast seminar had a special focus on protecting oncology innovations.

 

Some take-home-messages from the seminar:

  • Patents give you negotiation power, and is probably the biggest income source for Norwegian biotech start-ups.
  • Never publish anything on what you might wish to patent: Not even talk about it in a public meeting.
  • Researchers at University of Oslo and Oslo University Hospital: As soon as you think you have an innovation that could be patented, please contact Inven2 for advice.
    Researchers at other universities/university hospitals should contact their TTO`s.

 

Download presentations
All the presentations from the Oslo Cancer Cluster Incubator breakfast meeting may be downloaded below:

 

Targovax successfully completes a 70 MNOK financing

Immunotherapy specialist Targovax announces completion of a 70 MNOK financing, mainly from new investors. The share issue was significantly oversubscribed.

CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to develop Targovax as a company”.

Chairman Jónas Einarsson comments; “This is an important step forward for Targovax, and clearly shows that the Norwegian investment community has opened its eyes to our sector.”

Datum and partners represent the largest new group of shareholders, and look forward to working together with the company management in the years to come, to develop the company’s potential.

Arctic Securities ASA is the manager for the share issue. The company will be OTC-listed shortly after completion of the financing round.

Read more about Targovax here.

 



In Norwegian:

Immunterapi-spesialisten Targovax annonserer i dag gjennomføringen av en suksessfull kapitalutvidelse på 70 MNOK (11.5 MUSD), hovedsakelig fra nye investorer. Kapitalutvidelsen var vesentlig overtegnet.

CEO Hanne M Kristensen sier: “Kapitalutvidelsen på 70 MNOK gjør oss i stand til å fortsette å utvikle Targovax’ pipeline av immunterapi rettet mot RAS-muterte kreftformer, og gir oss en solid posisjon for å utvikle Targovax som selskap.“

Styreleder Jónas Einarsson kommenterer; “Dette er et viktig skritt fremover for Targovax og viser med all tydelighet at investormiljøet for alvor har fått øynene opp for vår sektor.“

Datum og partnere representerer den største nye gruppen av aksjonærer, og ser frem til å arbeide med selskapets ledelse i årene fremover for å utvikle selskapets potensial.

Arctic Securities ASA har vært tilrettelegger for kapitalutvidelsen. Selskapet vil bli OTC-listet kort tid etter gjennomføring av kapitalutvidelsen.

 

Breakfast seminar: Patents for beginners – Why should you protect your oncology innovation?

Oslo Cancer Cluster Incubator together with the Norwegian Industrial Property Office (Patentstyret) and Inven2 kindly invite researchers, clinicians and start-ups to learn more about securing IPR in oncology projects.

The topics that will be covered are:

  • Why is it important to protect your oncology innovation?
  • What can be patented, how to proceed and what is absolutely crucial in the process?
  • Securing IPR in oncology projects: challenges and strategies?

 

Date: Wednesday 18 June, 2014 at 8:00 -10:00 am. Breakfast will be served from 8:00 am. Venue: Seminar room FOBY2, the Research Building, OUS Radiumhospitalet, Ullernchausseen 70, Oslo. Please register here before 16 June, 2014. Program will follow soon. For more information please contact Susanne Werner, sw@oslocancercluster.no.

Bergen Bio Raises MNOK 75

BerGenBio AS, an oncology biopharmaceutical company, announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013.

Proceeds from the financing will be used to support the development of the Company’s innovative portfolio of innovative cancer therapeutics.This includes the on-going clinical development of its lead drug candidate, BGB324, a first-in-class selective AXL kinase inhibitor, which is currently in Phase Ib clinical studies to evaluate its safety and initial signs of efficacy to treat different cancers as a single agent and in combination with other drugs.

Fund pipeline advancement
The funds raised will be used to complete these studies, data from which is anticipated in 2015. BGB324 is the only selective Axl receptor tyrosine kinase inhibitor in clinical development to target tumour epithelial-mesenchymal transition (EMT) and has a potential application as a novel treatment for drug-resistant solid and hematological cancers, including non-small cell lung cancer and acute myeloid leukemia.

Richard Godfrey, CEO of BerGenBio commented: “I would like to thank our new and existing investors for their support. This important funding will enable us to advance our pipeline to key value inflection points. We believe that targeting Axl is a promising new approach to treating drug resistant cancers. We look forward to using this investment to continue exploring the clinical opportunity for our lead Axl inhibitor, BGB324, and our other candidate compounds.”

Huge market potential
Sveinung Hole, Managing Partner Sarsia Seed commented “At the seed stage we recognised the huge addressable market potential for BerGenBio`s EMT inhibitors and have continued to support the Company throughout its development. I am delighted the Company continues to attract funding and is able to progress its promising pipeline of novel targeted cancer therapies through further clinical development and realising significant value gain.

Ann-Tove Kongsnes, Investment Director, Investinor AS added, `we are excited by the Company’s prospects and are confident in the management team’s ability to drive these programs forward.”


About the Axl kinase receptor

The Axl tyrosine kinase receptor is regarded as one of the most promising new therapeutic targets for cancer drug  development It is upregulated in tumours residing in a hostile micro-environment and plays a crucial role in the epithelial-mesenchymal transition (EMT), which in turn is a key driver of metastasis (cancer spread) and a mechanisms of acquired drug-resistance.

About BerGenBio AS
BerGenBio AS is a biopharmaceutical company located in Bergen, Norway. The company is committed to developing first in class therapeutics that inhibit tumor EMT, preventing the formation of cancer stem cells and disrupting the important mechanisms of acquired cancer drug resistance. The company is founded on proprietary platform technology called CellSelect™, which uses information from RNAi screening studies to identify and validate novel drug targets and biomarkers. BGB324 is the first compound in BerGenBio’s pipeline to enter clinical trials, with additional compounds and drug targets at different stages of preclinical development. www.bergenbio.com

 

Oslo Cancer Cluster Innovation Park

Join the Oslo Cancer Cluster Innovation Park & Incubator

May 2015 is THE grand opening of Oslo Cancer Cluster Innovation Park and Oslo Cancer Cluster Incubator. Would you like to join us in the fight against cancer by being part of a power centre for developing innovative cancer treatment? Contact us now, and see what we may offer you as a tenant  in the Innovation Park or the Incubator.

With the opening of the Oslo Cancer Cluster Innovation Park, the whole value chain within oncology R&D in the Oslo-area is brought together at one place: The Radium Hospital Innovation Campus.

Oslo Cancer Cluster Innovation Park is made up of a ground space of two floors and three semi-separate buildings on top. Ullern High School with 900 students will inhabit the ground space. Here you will also find a cantina, a hall for multi-purpose use and a seminar room.

Already now, the Oslo Cancer Cluster Innovation Park is filling up. If you decide to join us, you will be in good company as well as in the heart of where innovative cancer R&D are being developed.

Oslo Cancer Cluster Incubator  – where budding biotechs bloom
The Oslo Cancer Cluster Incubator will provide a dynamic, creative and professional growth environment for scientists and start-ups within oncology, so that outstanding research is transformed into innovative therapies.

In the Incubator both researchers and start-ups may rent both office and lab space, scaling up and down as needed. The Incubator also provides a very attractive “plug and play” model – where all practicalities are taken care of.

Oslo Cancer Cluster Incubator receives financial support from the governmental agency Siva, the Industrial Development Corporation of Norway. The funding will be used to develop and implement a tailor made business development concept for the tenants of the Incubator.

Contact: 

Oslo Cancer Cluster Innovation Park
Jónas Einarsson
Initiator of the Oslo Cancer Cluster Innovation Park
Mobile: +47 480 96 355
E-mail: je@radforsk.no

Oslo Cancer Cluster Incubator
Ketil Widerberg
General Manager, Oslo Cancer Cluster
Mobile: +47 915 77 990
E-mail: kw@oslocancercluster.no

Norwegian Cancer Society initiate investment fund

The newly employed Head of Biotech Investments in The Norwegian Cancer Society, Sigrid Fossheim, has already had several meetings with potential oncology companies to invest in. – We aim to make our first investment before the Summer of 2014, says Fossheim.

The Norwegian Cancer Society is the largest private contributor to cancer research in Norway. Annually the Society grants approximately MNOK 180 to cancer research.

Earlier this year the Norwegian Cancer Society announced they would start investing in early-stage companies and projects within oncology. Head of Biotech Investments Sigrid Fossheim, known from Oslo Cancer Cluster members as Epitarget and Clavis Pharma, has already had meetings with several companies and Tech Transfer Offices (TTO`s), hoping to tap into the available funding of MNOK 75 over five years.
Will make a difference
“We have some specific criterias for our investments of course, but for us the overall goal is to accelerate the development of new therapies and diagnostics for the benefit of the cancer patients. The rule of thumb when we invest is, that we will make a difference, meaning the funding should release the potential of a project and help the company through a critical phase where capital is scarce, says Fossheim

And adds: “A successful investment from our perspective implies that the company for instance has been able to undertake critical and risk reducing project activities rendering it more attractive to larger investors that can further finance the company to project commercialisation and patient benefit.”

As a general rule at least one co-investor should invest in the project or company in collaboration with the Norwegian Cancer Society.

“Having a co-investor is important for us in order to learn the do`s and don’ts of the trade. We have a tight dialogue with all actors in the field, both public and private, including the TTO`s,” says Ole Alexander Opdalshei, Deputy Secretary General.


Hope to inspire others to invest

The news that the Norwegian Cancer Society would start investing was very well received by the oncology community when the initiative was first announced in May this year. For the Society this is an entirely new role, and a very different role than funding cancer research, says Opdalshei.

“For us this is a political statement as well. We hope that through investing, the government and private investors understand that there is a huge need for capital to take oncology research from bench to bedside. We see too few promising projects reach the cancer patients, due to lack of funding in some critical phases. Hopefully our entry onto this scene will inspire others to take the leap – in collaboration with us,” says Opdalshei.

The Society will at the start of the 2014  have meetings with both Innovation Norway and the Norwegian Research Council, addressing the need for more early-stage funding in this area.

“We were very surprised and let down when we got the news that none of the governmental seed capital funds went to biomedicine. This is an area that deserves funding to transform the excellent research to actual patient care, says Opdalshei.

Contact us and set up a meeting
Fossheim encourages oncology start-ups and TTO`s that need funding, to contact her and set up a meeting for a first evaluation.

“If the company or TTO has a promising project that falls within the scope of the Society’s investment mandate, we will encourage the company/TTO to apply for investment funds, following some overall guidelines and providing the necessary documentation. If the evaluation of the company is positive with amongst other the fulfillment of the Society’s investment criterias – an investment proposal will be presented to the Investment Committee for recommendation. The board of the Norwegian Cancer Society will however have the final decision-making authority with regard to investments recommended by the Investment Committee, “says Fossheim.

Flowchart investment process Norwegian Cancer Society.

Facts – Norwegian Cancer Society`s Investments in Oncology:

  • MNOK 75 over a five-year period
  • Early-stage companies/projects
  • Investment criterias at an organizational level:
    1) Unlisted companies
    2) Main business area within oncology
    3) Well –organised and professionally run projects/companies
  • Investment criterias at a project level:
    1) Unique product with high potential for improved cancer care
    2) Unmet medical needs addressed
    3) Patent protection
    4) Competent and experienced team
    5) Proven capability in project execution
    6) Clear and achievable milestone plan
    7) Robust and suitable business model
    8) Low negative, reputation risk
    9) Conformity with the ethical guidelines of the Norwegian Cancer Society

Investment Committee members:

  • Terje Kalland, Chief Scientific Officer, Karolinska Development
  • Hans Peter Bøhn, physician and former healthcare analyst at Fondsfinans
  • Tom Pike, life science industry professional
  • Hilde Steineger, Head of Innovation Management, Pronova Biopharma
  • James Lorens, Professor at University of Bergen and co-founder of BerGenBio


For more information:

Contact Sigrid Fossheim, Head of Biotech Investments, The Norwegian Cancer Society: sigrid.fossheim@kreftforeningen.no /+ 47 982 38 465


About the Norwegian Cancer Society

The Norwegian Cancer Society is a nationwide organization that addresses the challenges of cancer and funding research is its main priority. The Society provides approximately 25 per cent of all direct funding for cancer research in Norway, and is also actively involved in cancer prevention and international collaboration.
The Society’s main goals are s to reduce cancer incidence, increase cancer survival and achieve optimal life quality for cancer patients and their families.
Read more on the Norwegian Cancer Society’s website.

 

Helsemyggordning – financial instrument for health innovation

December 11th 2013, Oslo Cancer Cluster, Oslo Medtech and Nansen Neuroscience Network launched a proposal for a new financing mechanism to stimulate innovation from the health- and biotech industry.

The proposal was very well received among the politicians, industry, public organisations and investors at the debate meeting in conjunction to the launch. Conservative Member of Parliament Kristin Vinje viewed the scheme as an exciting proposition that it is worthwhile to investigate further.

The three health clusters have named the scheme “Helsemyggordning”, building on a similar financial instrument from the oil and gas industry that was established to encourage exploration and development activity among young and small petroleum companies.

To stimulate increased health innovation, the scheme “Helsemyggordning” would involve cash payments of tax deduction related to the cost of development and testing of health products and health technologies innovators who are not liable to tax. When the company gets profits and are liable to tax, they must repay the tax paid for the development and testing costs. The system thus acts as an interest-free capital loans from state to the health innovations.

Acting CEO in Oslo Cancer Cluster, Jónas Einarsson, says the scheme may  trigger the huge potential within Norwegian health R&D. “We are at a critical stage now, as the biotech projects coming out are more mature and in a need for early funding,” says Einarsson.

Menon Business Economics have analysed “Helsemyggordningen”. They conclude that it is easy to administrate, predictable, and targeted.

Please find more in debth information here:

Report on “Helsemyggordningen”

Presentation of Helsemyggordningen, by Erik Jacobsen, Menon Business Economics.

Horizon 2020: Major possibilities

Horizon 2020 is the new European Framework Program for Research and Innovation. Oslo Cancer Cluster encourage our members to take a closer look at the possibilities Horizon 2020 represents for funding R&D oncology projects and also taking part in international networks.
Norwegian participation in the EU framework programs has been of critical importance to Norwegian research, enabling Norwegian researchers, research institutions and companies to take part in larger international networks.

The Norwegian Research Council has recently been touring most of Norway hosting information meetings on Horizon 2020. The program will take effect from January 2014 and the budget is of around 70 billion Euros over a seven year period. This is a large increase from the last framework program.


Horizon 2020 incorporates three overall areas of funding – and there is a specific focus on SMEs and also on academic-industry collaboration within the program:

  • Funding for basic research to support curiosity-driven, innovative research and large-scale cooperation on research infrastructure
  • Funding to strengthen industrial leadership and competitiveness with the help of effective industry-oriented funding instruments
  • Funding for research and innovation activities to solve shared societal challenges

Under the topic “Health, demographic change and wellbeing”, there are seven focus areas:
1. Understanding health, ageing & disease
2. Effective health promotion, disease prevention, preparedness and screening
3. Improving diagnosis
4. Innovative treatments and technologies
5. Advancing active and healthy ageing
6. Integrated, sustainable, citizen-centred care
7. Improving health information, data exploitation and providing an evidence base for health policies and regulation

More information may be found here:
The Norwegian Research Council webpage
Draft Work Programs 2014-2015
Newsletter – Program for Health, demographic change and wellbeing

Important deadlines:

  • Horizon 2020 national launch events: October 2013 to January 2014
  • Adoption of work programme and publication of first calls for proposals: December 11 2013
  • Expression of interest: Medio January 2014

 Background material presented by the Research Council on the information meeting in Oslo in November 2013:

Investinor and Industrifonden invest in Pharmalink

Oslo Cancer Cluster was the proud host of a press conference in early October, where two of the Nordic region’s largest governmental venture investors Investinor and Industrifonden announced their NOK million 90 investment in Swedish biotech Pharmalink. Pharmalink is a specialty pharma company focused on orphan and niche products within cancer and renal disease.

The press conference was hosted by Oslo Cancer Cluster due to Pharmalinks future plans of joining the cluster and becoming a part of the strong oncology environment in Oslo.

Jónas Einarsson, acting director of Oslo Cancer Cluster states “I am very glad to hear that Pharmalink would like to join Oslo Cancer Cluster and I welcome them to be a part of our strong member organization. I am also very happy for the collaboration between Investionor and Industrifonden within biotech, and hope for more co-investments in the close future.”

This is the second co-investment Investionor and Industrifonden have made in collaboration, the first one was also in biothech: Norwegian company Smartfish that produce nutraceuticals for cancer patients among others.

In the picture from the press conference you see from the left Investment director from Investinor og member of the board of Pharmalink Ann-Tove Kongsnes, CEO of Investinor Geir Ove Kjesbu, CEO of Industrifonden Claes De Neergaard and CEO of Pharmalink Johan Häggblad. Photo: Anne-Elisabeth Næss.

Below the facts you may read the press releases from both Investionor (In Norwegian) and Pharmalink (In English) on the investment:

Facts:

About Pharmalink
Pharmalink is a Swedish specialty pharma company developing high value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical development and marketing to identify and progress products that address significant unmet medical needs. With a successful history in pharmaceutical sales and marketing, and highly experienced, dynamic management team, Pharmalink is focused on the development and commercialization of valuable, de-risked projects. It has two late-stage clinical phase products under development, Nefecon® and Busulipo™. Pharmalink is actively seeking opportunities to acquire or in-licence product opportunities in niche and hospital care indications. Visit www.pharmalink.se for further information.

About Industrifonden
Industrifonden is one of Sweden’s largest and most experienced investors at early stage and in growth companies and manages an evergreen fund of approximately 3.5 billion (EUR420m). It has for the last 30 years had a leading role in the development of Swedish life science companies. Founded by the Swedish government in 1979, Industrifonden is an independent venture capital fund that operates on a strictly commercial basis and receives no further government funding. Revenues are returned to the business for new investments. See more info at: www.industrifonden.se

About Investinor
Investinor is Norway’s largest investor in venture and expansion capital, and manages a NOK4.2 billion (EUR525m) evergreen fund. Investinor was founded in 2008 and is funded by the Norwegian government. It invests directly in promising unlisted companies and on the same terms and conditions as private investors, with a clear exit strategy for all investments.
Find more info on: www.investinor.no